In the present study the role of L-arginine/nitric oxide (NO)/cGMP pathway in the antinociceptive activity of pyridoxine in p-benzoquinone-induced abdominal constriction test in mouse was investigated. Pyridoxine (CAS 58-56-0) displayed dose-dependent antinociceptive activity at 0.0625−1 mg/kg (s.c.) doses. L-arginine (CAS 1119-34-2), a NO precursor, displayed a triphasic pattern as antinociception-nociceptionantinociception (61.8 ± 7.8, −36.5 ± 12.7 and 17.0 ± 4.3 %, 5, 40 and 50 mg/kg, s.c., respectively). The antinociceptive effect of pyridoxine at ED 50 dose (0.43 mg/ kg, s.c.) (47.7 ± 3.9 %) was significantly decreased by L-arginine at 40 and 50 mg/ kg doses (4.1 ± 9.3 and 37.8 ± 1.6 %, respectively) while 5 mg/kg dose of L-arginine significantly potentiated the pyridoxine analgesia. On the other hand, pyridoxine reversed the L-arginine-induced nociception to antinociception (4.1 ± 9.3 %) and augmented the antinociceptive effect of L-arginine (37.8 ± ZusammenfassungDie Rolle von L-Arginin/Stickoxid in der antinozizeptiven Aktivität von Pyridoxin bei Mäusen Ziel dieser Studie war es, die Rolle von L-Arginin/Stickoxid (NO)/cGMP in der antinozizeptiven Aktivität von Pyridoxin im p-Benzochinon.induzierten abdominal Spannungstest zu untersuchen. Pyridoxin (CAS 58-56-0) zeigte eine dosisab-1.6 %). L-N G -nitroarginine methyl ester (CAS 51298-62-5), a NO synthase inhibitor, at 75 mg/kg, s.c. produced antinociception and significantly increased the antinociceptive effect of pyridoxine (63.7 ± 1.2 %). Methylene blue (CAS 61-73-4, MB), a guanylyl cyclase and/or NO synthase inhibitor, was antinociceptive and nociceptive at 5 and 40 mg/kg doses, respectively. 5 mg/kg dose of MB significantly increased the antinociceptive effect of pyridoxine, but did not change it at 40 mg/kg dose. On the other hand, pyridoxine significantly decreased the antinociceptive effect of MB and reversed the MB-induced nociception to antinociception. Combination of pyridoxine and morphine (CAS 57-27-2) (ED 50 : 0.13 mg/kg, s.c.) at 49.8 ± 1.9 % revealed a significant antinociceptive potentiation (69.1 ± 1.8 %). The findings of the present study emphasise the contribution of central and/or peripheral L-arginine/NO/ cGMP nociceptive processes in pyridoxine-induced antinociception. hängige antinozizeptive Aktivität in einer subkutanen Dosis von 0,0625-1 mg/kg. L-Arginin (CAS 1119-34-2), ein NO-Precursor, zeigte ein Drei-Phasen-Muster: Antinozizeption-NozizeptionAntinozizeption ( 61.8 ± 7.8, 36.5 ± 12.7 bzw. 17.0 ± 4.3 %, 5, 40 bzw. 50 mg/kg, s.c.). Der antinozizeptive Effekt von Pyridoxin bei Verwendung der ED 50 (0.43 mg/kg, s.c.) (47.7 ± 3.9) wurde von L-ArgiKey words L-Arginine/NO/cGMP, role in antinociception CAS 58-56-0 CAS 1119-34-2 Pyridoxine, antinociceptive effect, mouse Arzneim.-Forsch./Drug Res. 51 (II), 832−838 (2001) Arzneim.-Forsch./Drug Res. 51 (II), 832−838 (2001) 832 Abacıoglu, et al. − L-Arginine/nitric oxide pathway
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.